allergytalk

AllergyTalk Episode 32: How Does the Atopic March Differ in Black and White Children?

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!

Today we are again joined by Dr. Vivian Hernandez-Trujillo from Nicklaus Children’s Hospital and will be reviewing the July-Aug 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations.

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.

Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience.

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

 

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Hernandez-Trujillo: 

Speaker Takeda, CSL

Advisory boards Takeda, Regeneron, Sanofi

Consultant  Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Episode 31: The Presentation of an Inborn Error of Immunity Is Not Always Infection!

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!

Today we are again joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations.

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.

Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience.

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

 

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Montanaro has done research with AstraZeneca, Regeneron, Theravance, and Teva

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst, Novartis

Episode 30: Is COVID Vaccine Skin Testing Useful?

Welcome to Season Two of Allergytalk! Starting with this episode, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!

Today we are joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis.

First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing.

Differences in oral food challenge reaction severity based on increasing age in a pediatric population.

 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Severe Pediatric Asthma Miniseries - Episode 3

Episode 3: Severe pediatric asthma-beyond standard therapy, the role of current and future therapies including biologics

Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.  

Learning Objectives:

1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population
2. Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population
3. Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma

References:              

1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).
2. Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021.
3. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14.
4. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

Severe Pediatric Asthma Miniseries - Episode 2

Episode 2:       Severe pediatric asthma-evaluation of the child, diagnostic testing, assessing steroid side effects

 

Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.  

Learning Objectives:

1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population
2. Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population
3. Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma

References:              

1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).
2. Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021.
3. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14.
4. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

Severe Pediatric Asthma Miniseries - Episode 1

Episode 1: Severe pediatric asthma-burden of disease, adherence issues, and comorbidities

 

Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.  

Learning Objectives:

1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population
2. Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population
3. Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma

References:              

1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).
2. Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021.
3. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14.
4. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

CRSwNP Miniseries: Episode 3

Episode 3 discusses access to treatment disparities for nasal polyposis in minority and underserved populations.

 

Today’s speakers have the following disclosures:

Gerald Lee, MD: Nothing to disclose

Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose
Anjeni Keswani, MD: Nothing to disclose

 

This podcast series is supported by Sanofi Regeneron.

CRSwNP Miniseries: Episode 2

Episode 2 discusses the impact of air pollution and the environment on CRSwNP and how this disproportionately affects minority and underserved populations.

 

Today’s speakers have the following disclosures:

Gerald Lee, MD: Nothing to disclose

Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose
Anjeni Keswani, MD: Nothing to disclose

 

This podcast series is supported by Sanofi Regeneron.

CRSwNP Miniseries: Episode 1

Episode 1 provides an overview of the subtypes of CRSwNP and reviews the evidence for disparities in the burden of disease on minority and underserved populations and discusses the reasons for these disparities.

 

Today’s speakers have the following disclosures:

Gerald Lee, MD: Nothing to disclose

Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose

Anjeni Keswani, MD: Nothing to disclose

 

This podcast series is supported by Sanofi Regeneron.

Disparities in Atopic Dermatitis Miniseries: Episode 3: Improving Access to Treatment for Atopic Dermatitis in Minority and Underserved Populations

This episode will describe best practices for addressing disparities in care for patients with atopic dermatitis and how to implement specific health equity strategies to improve access to atopic dermatitis care and increase patient adherence to treatment.

Disparities in Atopic Dermatitis Miniseries

Host: Payel Gupta, MD, FACAAI
Expert: Anil Nanda, MD, FACAAI
Expert: Andrew Alexis, MD, MPH
Expert: Marcella Aquino, MD, FACAAI

The miniseries is hosted by Payel Gupta, MD,  a triple board-certified specialist and the Medical Director for Allergy, Asthma, Immunology & ENT at LifeMD.com. She is practicing in New York City and is an assistant clinical professor at SUNY Downstate Medical Center and Clinical Instructor at Mount Sinai Medical Center.  She is a volunteer national spokesperson for the American Lung Association and co-host of The Itch Podcast. Joining her are Anil Nanda, MD, who is in private community practice at the Asthma and Allergy Center in Lewisville and Flower Mound, Texas and is Clinical Associate Professor of Medicine, at the Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX; Andrew F. Alexis, MD, MPH, who is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. He is the former Chair of the Department of Dermatology at Mount Sinai Morningside and Mount Sinai West. Having served as Director of the first-of-its-kind Skin of Color Center for over 15 years, his work has helped to advance patient care, research, and education pertaining to dermatologic disorders that are prevalent in populations with skin of color; and Marcella Aquino, MD, who is an Associate Professor of Pediatrics at the Warren Alpert Medical School of Brown University and staff at Rhode Island Hospital/Hasbro Children’s Hospital. Her interests include allergic skin diseases particularly allergic contact dermatitis, atopic dermatitis, and drug allergy. She has presented on these topics at national meetings and published in textbooks and peer reviewed journals with a focus on contact dermatitis including patch testing, the role of contact dermatitis in atopic dermatitis patients, drug allergy challenges/desensitizations and the use of simulation for the instruction of anaphylaxis/allergic emergencies. Dr. Aquino was awarded an implementation grant by the ACAAI Foundation looking a multi-level contributing factors to racial and ethnic disparities in urban children in asthma and atopic dermatitis.

This podcast series is supported by Pfizer.